Journal
PROTEOMICS CLINICAL APPLICATIONS
Volume 10, Issue 6, Pages 635-644Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/prca.201500069
Keywords
Autoimmune disease; Protein glycosylation; Sialic acid; Siglec receptor
Funding
- Department of Education and Learning, Northern Ireland, UK
- European Union Regional Development Fund (ERDF) EU Sustainable Competitiveness Programme for N. Ireland & the Northern Ireland Public Health Agency (HSC RD)
Ask authors/readers for more resources
Autoimmune diseases (ADs) are currently treated with anti-inflammatory and immunosuppressive drugs, aimed at reducing symptoms of disease in order to improve quality of life for patients. However, for a significant number of patients these therapies are ineffective, leading to an increased risk of irreversible damage and eventual disability in certain cases. Growing evidence has implicated glycosylated proteins and their cognate receptors in modulation of the autoimmune response. This review will summarize these findings with particular focus on sialic acid-binding immunoglobulin-like lectin (Siglec)-1 and Siglec-2 involvement in AD. Fluctuations in these glycosylation-dependent pathways could act as sentinels of disease activity or drug responses. If validated, protein modification and cellular response markers could help clinicians achieve remission earlier.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available